The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
Official Title: Phase II Pilot Study Evaluating the Neoadjuvant Combination "Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and "Triple Negative" Breast Cancer Patients. TENEO Study.
Study ID: NCT00600249
Brief Summary: The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination "Taxotere-Erbitux".
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Centre Jean Perrin, Clermont-Ferrand, , France
CHU Albert Michallon, Grenoble, , France
Centre Oscar Lambret, Lille, , France
Centre Hospitalier, Montluçon, , France
Institut de Cancérologie de la LOIRE, Saint Priest en Jarez, , France
Hôpital Georges Pianta, Thonon les Bains, , France
Name: Philippe Chollet, MD
Affiliation: Centre Jean Perrin
Role: PRINCIPAL_INVESTIGATOR